Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciad703 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Dariusz A Hareza und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: beta-Lactamases, Anti-Bacterial Agents, Enterobacteriaceae Infections, Microbial Sensitivity Tests. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCEZID CDC HHS, NIH HHS.
Abstract (Originalsprache)
Background
Investigations into antibiotics for extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) bloodstream infections (BSIs) have focused on blaCTX-M genes. Patient outcomes from non–CTX-M-producing ESBL-E BSIs and optimal treatment are unknown.
Methods
A multicenter observational study investigating 500 consecutive patients with ceftriaxone-resistant Enterobacterales BSIs during 2018–2022 was conducted. Broth microdilution and whole-genome sequencing confirmed antibiotic susceptibilities and ESBL gene presence, respectively. Inverse probability weighting (IPW) using propensity scores ensured patients with non–CTX-M and CTX-M ESBL-E BSIs were similar before outcome evaluation.
Results
396 patients (79.2%) were confirmed to have an ESBL-E BSI. ESBL gene family prevalence was as follows: blaCTX-M (n = 370), blaSHV (n = 16), blaOXY (n = 12), and blaVEB (n = 5). ESBL gene identification was not limited to Escherichia coli and Klebsiella species. In the IPW cohort, there was no difference in 30-day mortality or ESBL-E infection recurrence between the non–CTX-M and CTX-M groups (odds ratio [OR], 0.99; 95% confidence interval [CI], .87–1.11; P = .83 and OR, 1.10; 95% CI, .85–1.42; P = .47, respectively). In an exploratory analysis limited to the non–CTX-M group, 86% of the 21 patients who received meropenem were alive on day 30; none of the 5 patients who received piperacillin-tazobactam were alive on day 30.
Conclusions
Our findings suggest that non–CTX-M and CTX-M ESBL-E BSIs are equally concerning and associated with similar clinical outcomes. Meropenem may be associated with improved survival in patients with non–CTX-M ESBL-E BSIs, underscoring the potential benefit of comprehensive molecular diagnostics to enable early antibiotic optimization for ESBL-E BSIs beyond just blaCTX-M genes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Ares Genetics, Vienna, Austria.
- Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Pranita D Tamma
Förderung
- NIAID NIH HHS
- NCEZID CDC HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Hareza, D. A., Cosgrove, S. E., Simner, P. J., Harris, A. D., Bergman, Y., Conzemius, R., Jacobs, E., Beisken, S., & Tamma, P. D. (2024). Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad703
Vancouver
Hareza DA, Cosgrove SE, Simner PJ, Harris AD, Bergman Y, Conzemius R, et al. Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad703
BibTeX
@article{Hareza2024,
author = {Hareza, Dariusz A and Cosgrove, Sara E and Simner, Patricia J and Harris, Anthony D and Bergman, Yehudit and Conzemius, Rick and Jacobs, Emily and Beisken, Stephan and Tamma, Pranita D},
title = {Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciad703}
}
EUVIMED